NASDAQ:MRSN Mersana Therapeutics (MRSN) Stock Price, News & Analysis $1.64 +0.11 (+6.86%) (As of 11:15 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Mersana Therapeutics Stock (NASDAQ:MRSN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mersana Therapeutics alerts:Sign Up Key Stats Today's Range$1.47▼$1.6450-Day Range$1.53▼$2.6852-Week Range$1.22▼$6.28Volume275,278 shsAverage Volume1.58 million shsMarket Capitalization$201.98 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingModerate Buy Company OverviewMersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Read More… Mersana Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks86th Percentile Overall ScoreMRSN MarketRank™: Mersana Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 143rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingMersana Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMersana Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Mersana Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mersana Therapeutics are expected to grow in the coming year, from ($0.61) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 5.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.08% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Mersana Therapeutics has recently decreased by 7.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-0.69 Percentage of Shares Shorted7.08% of the outstanding shares of Mersana Therapeutics have been sold short.Short Interest Ratio / Days to CoverMersana Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Mersana Therapeutics has recently decreased by 7.11%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentMersana Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mersana Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for MRSN on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows1 people have added Mersana Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,440.00 in company stock.Percentage Held by Insiders11.80% of the stock of Mersana Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.92% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mersana Therapeutics' insider trading history. Receive MRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRSN Stock News HeadlinesMersana Therapeutics: We're About To Find Out If ADC Platform Is More TolerableDecember 19, 2024 | seekingalpha.comPromising Clinical Data and Valuation Support Mersana Therapeutics’ Buy RecommendationDecember 17, 2024 | markets.businessinsider.comGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. December 24, 2024 | Crypto 101 Media (Ad)Buy Rating for Mersana Therapeutics: Anticipated XMT-1660 Data as Key CatalystNovember 15, 2024 | markets.businessinsider.comMersana Therapeutics transferred with Buy rating at CitiNovember 15, 2024 | markets.businessinsider.comMersana Therapeutics Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)November 15, 2024 | markets.businessinsider.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comSee More Headlines MRSN Stock Analysis - Frequently Asked Questions How have MRSN shares performed this year? Mersana Therapeutics' stock was trading at $2.32 at the beginning of 2024. Since then, MRSN stock has decreased by 32.3% and is now trading at $1.5695. View the best growth stocks for 2024 here. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics, Inc. (NASDAQ:MRSN) released its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.08. The business's revenue was up 63.6% on a year-over-year basis. When did Mersana Therapeutics IPO? Mersana Therapeutics (MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Mersana Therapeutics' major shareholders? Top institutional investors of Mersana Therapeutics include State Street Corp (2.22%), Geode Capital Management LLC (1.97%), Verition Fund Management LLC (1.06%) and Acuta Capital Partners LLC (0.98%). Insiders that own company stock include Andrew A F Hack, Anna Protopapas, Martin H Jr Huber, Brian Deschuytner, Alejandra Carvajal, Mohan Bala, Ashish Mandelia, Arvin Yang, Tushar Misra and Timothy B Lowinger. View institutional ownership trends. How do I buy shares of Mersana Therapeutics? Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mersana Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Saia (SAIA), Rambus (RMBS), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings11/13/2024Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRSN CUSIPN/A CIK1442836 Webwww.mersana.com Phone(617) 498-0020FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+292.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-171,670,000.00 Net Margins-214.20% Pretax Margin-212.99% Return on Equity-401.37% Return on Assets-38.61% Debt Debt-to-Equity Ratio13.35 Current Ratio2.35 Quick Ratio2.35 Sales & Book Value Annual Sales$34.84 million Price / Sales5.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book4.94Miscellaneous Outstanding Shares123,533,000Free Float108,956,000Market Cap$189.01 million OptionableOptionable Beta1.40 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:MRSN) was last updated on 12/24/2024 by MarketBeat.com Staff From Our Partners"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.